Published in Medical Letter on the CDC and FDA, July 17th, 2005
"Two recombinant vaccines against Theileria parva, based on a near full-length version of the sporozoite surface antigen p67 (p67635 ), or an 80 amino acid C-terminal section (p67C), were evaluated by exposure of immunized cattle to natural tick challenge in two sites at the Kenya Coast and one in Central Kenya. Vaccination reduced severe ECF by 47% at the coast and by 52% in central Kenya from an average incidence of 0.53±0.07 (SE) in 50 non-immunized controls to an average of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.